Sara Cheraghi, Maryam Honardoost, Fereshteh Abdolmaleki, Mohammad E Khamseh
{"title":"甲状腺乳头状癌患者固定切片标本细针抽吸细胞学中的 BRAFV600E 基因突变分析","authors":"Sara Cheraghi, Maryam Honardoost, Fereshteh Abdolmaleki, Mohammad E Khamseh","doi":"10.47176/mjiri.38.83","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAF<sup>V600E</sup> mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.</p><p><strong>Methods: </strong>Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAF<sup>V600E</sup> mutation by pyrosequencing of extracted DNA.</p><p><strong>Results: </strong>BRAF<sup>V600E</sup> mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.</p><p><strong>Conclusion: </strong>BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.</p>","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":"38 ","pages":"83"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11644031/pdf/","citationCount":"0","resultStr":"{\"title\":\"BRAF<sup>V600E</sup> Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.\",\"authors\":\"Sara Cheraghi, Maryam Honardoost, Fereshteh Abdolmaleki, Mohammad E Khamseh\",\"doi\":\"10.47176/mjiri.38.83\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAF<sup>V600E</sup> mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.</p><p><strong>Methods: </strong>Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAF<sup>V600E</sup> mutation by pyrosequencing of extracted DNA.</p><p><strong>Results: </strong>BRAF<sup>V600E</sup> mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.</p><p><strong>Conclusion: </strong>BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.</p>\",\"PeriodicalId\":18361,\"journal\":{\"name\":\"Medical Journal of the Islamic Republic of Iran\",\"volume\":\"38 \",\"pages\":\"83\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11644031/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Journal of the Islamic Republic of Iran\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47176/mjiri.38.83\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.38.83","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
BRAFV600E Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.
Background: Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAFV600E mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.
Methods: Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAFV600E mutation by pyrosequencing of extracted DNA.
Results: BRAFV600E mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.
Conclusion: BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
